Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Grit Biotechnology logo — Developing novel cell therapies to transform the lives of pe...

Grit Biotechnology

Developing novel cell therapies to transform the lives of people with cancer.

Founded 2019 China China 10 employees Series B Total: $415.00M Biotechnology, Health Care +1

General Information

Company Name Grit Biotechnology
Founded Year 2019
Location China China
Employees 10
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Grit Biotechnology. To contact Grit Biotechnology, visit grit-bio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Grit Biotechnology compare?

A PDF of Grit Biotechnology and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Grit Biotechnology soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Grit Biotechnology

Grit Biotechnology is a Chinese biotechnology company founded in 2019, with the slogan "Developing novel cell therapies to transform the lives of people with cancer." The company focuses on developing tumor-infiltrating lymphocyte (TIL) therapy programs to address unmet medical needs for patients with solid tumors. Their product GT101, the first non-gene-modified TIL product to receive Investigational New Drug (IND) approval in China, is currently in Phase 1 clinical trials. Grit Bio has established three core technology platforms for TIL development: StaViral®, a retroviral system tailored for TIL engineering, ImmuT Finder®, a high-throughput screening platform identifying novel T-cell targets, and StemTexp®, a TIL expansion platform that enriches TCM and TSCM populations of TIL. The company is leveraging these platforms to develop a potentially best-in-class gene-engineered TIL therapy. In its latest funding round, Grit Biotechnology raised CNY400.00M in a Series B investment on 08 September 2023. The investors in this round included Matrix Partners China, Decheng Capital, CICC, Yuanhe Capital, HeFangTian Venture Partnership, Qianhai Ark, Liando Group, and Sherpa Healthcare Partners. This investment signifies the confidence of prominent venture capital firms in Grit Bio's vision and potential in the biotechnology and healthcare industries.

Business keywords: Cell Therapy, TIL Therapy, Cancer Treatment, Clinical Trials, Tumor-Infiltrating Lymphocytes, Immunotherapy, Gene Engineering, StaViral, ImmuT Finder, StemTexp, Solid Tumors, China, Startup, Investment

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY400.00M 8
Matrix Partners China Decheng Capital CICC
Matrix Partners China, Decheng Capital +6
08 Sep 2023
Series A Undisclosed 2
Decheng Capital Hillhouse Investment
Decheng Capital, Hillhouse Investment
14 Jul 2021
Series A $15.00M -
01 Dec 2020

Grit Biotechnology Alternatives & Competitors

View All Alternatives
Grit Biotechnology vs
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. United States

Iovance is a patient-centric, collaborative organization that is driven to change the way cancer is...

IPO
925 employees
Biotechnology, Health Care
Compare Grit Biotechnology vs Iovance Biotherapeutics, Inc.
Grit Biotechnology vs
Pyxis Oncology
Pyxis Oncology United States

Charting a course to therapeutics for difficult-to-treat cancer.

68 employees
Biotechnology, Health Care
Grit Biotechnology vs
Seneca Therapeutics, Inc.
Seneca Therapeutics, Inc. United States

Seneca Therapeutics is developing a novel cancer therapy (oncolytic immunotherapeutic) for patients...

Series B
10 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Grit Biotechnology

Developing novel cell therapies to transform the lives of people with cancer.
Grit Biotechnology was founded in 2019.
Grit Biotechnology is headquartered in China.
Grit Biotechnology operates in Biotechnology, Health Care and Medical Devices. Its work centres on Cell Therapy, TIL Therapy, Cancer Treatment and Clinical Trials.
Grit Biotechnology has approximately 10 employees.
Grit Biotechnology has completed 3 funding rounds, raising a total of $415.00M. The latest funding stage is Series B.
Top alternatives and competitors to Grit Biotechnology include Iovance Biotherapeutics, Inc., Pyxis Oncology, Seneca Therapeutics, Inc., Neogene Therapeutics, Carisma Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Grit Biotechnology and Iovance Biotherapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Grit Biotechnology, https://bouncewatch.com/company/grit-biotechnology, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout